Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual Roles of hABCB1 in Drug Resistance and Immune Evasion: Implications for Lung Cancer Therapy.

ACS omega·2026
Same author

Engineering a self-organized enzyme cascade for enhanced cell-free biosynthesis of 3-hydroxypropionic acid.

Protein science : a publication of the Protein Society·2026
Same author

ONEST: a web-based platform for the rapid and robust analysis of protein excited states through CEST spectroscopy.

Bioinformatics (Oxford, England)·2026
Same author

Orthogonal Tri-Modular Coiled-Coil Assembly for Programmable Multi-Cargo Display on Escherichia coli Nissle 1917.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Laser-Induced Porosity Engineering of Metal-Organic Frameworks for Enhanced CO<sub>2</sub>/CH<sub>4</sub> Adsorption Properties.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

NaF@MnO-Based Sacrificial Cathode/Separator Composite for Boosting the Energy Density of Sodium-Ion Batteries.

ACS nano·2026

Related Experiment Video

Updated: May 7, 2026

Manufacture and Drug Delivery Applications of Silk Nanoparticles
09:03

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Published on: October 8, 2016

16.5K

Self-Decorating Albumin Nanoparticles as a Modular Drug Delivery Platform.

Jong-Ha Park1, Yong Joon Cho1, Sang-Yeop Lee2,3

  • 1Department of Chemical Engineering, Pukyong National University, Yongso-ro 45, Nam-gu, Busan 48513, Republic of Korea.

ACS Biomaterials Science & Engineering
|December 8, 2025
PubMed
Summary
This summary is machine-generated.

This study introduces variant human serum albumin (HSA) nanoparticles (VA-NPs) that can self-decorate with proteins. This novel platform offers a scalable solution for advanced nanomedicines with improved targeting and efficacy.

Keywords:
TRAILcoiled-coildrug deliveryhuman serum albuminnanoparticleself-assembly

More Related Videos

Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation
06:57

Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation

Published on: August 11, 2018

8.4K
Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

8.7K

Related Experiment Videos

Last Updated: May 7, 2026

Manufacture and Drug Delivery Applications of Silk Nanoparticles
09:03

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Published on: October 8, 2016

16.5K
Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation
06:57

Rapid, Scalable Assembly and Loading of Bioactive Proteins and Immunostimulants into Diverse Synthetic Nanocarriers Via Flash Nanoprecipitation

Published on: August 11, 2018

8.4K
Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

8.7K

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Drug Delivery Systems

Background:

  • Human serum albumin nanoparticles (HSA-NPs) enhance drug delivery but rely on passive tumor targeting.
  • Current active targeting methods for HSA-NPs can cause immune responses and face production challenges.
  • Scalable and consistent manufacturing of HSA-NPs with specific functionalities remains a significant hurdle.

Purpose of the Study:

  • To develop a novel nanocarrier platform using variant human serum albumin (VA) for enhanced nanoparticle functionality.
  • To create a modular system for self-decoration of nanoparticles with diverse payload proteins.
  • To overcome limitations of passive targeting and chemical conjugation in current nanoparticle drug delivery.

Main Methods:

  • Engineered a variant human serum albumin (VA) with an α-helical domain for specific protein interactions.
  • Utilized spontaneous coiled-coil interactions for self-decoration of VA-based nanoparticles (VA-NPs) with payload proteins.
  • Demonstrated a modular platform eliminating the need for chemical conjugation or genetic fusion.

Main Results:

  • VA-NPs exhibit spontaneous and specific self-decoration with payload proteins via coiled-coil interactions.
  • This method provides a programmable protein display on the nanoparticle surface.
  • The approach offers a scalable and clinically relevant alternative to traditional nanoparticle functionalization.

Conclusions:

  • VA-NPs represent a novel, modular platform for creating multifunctional nanomedicines.
  • This programmable protein display strategy addresses limitations in nanoparticle specificity, versatility, and scalability.
  • The technology paves the way for next-generation nanomedicines with enhanced therapeutic efficacy.